Abstract: The present invention relates to methods of measuring cellular proliferation using ectoenzymes such as membrane-bound chitobiase (N,N′-diacetylchitobiase) and nucleic acids for use in such methods.
Abstract: Methods and compositions for the inactivation and removal of contaminants of a biological composition are disclosed. The methods include the steps of: (a) contacting the biological composition with an inactivating agent including an aziridino moiety, such as ethyleneimine, an oligomer of ethyleneimine, or a haloderivative salt of either ethyleneimine or an oligomer of ethyleneimine, where a portion of the agent reacts with and inactivates the contaminant, and a portion of the agent remains unreacted; (b) contacting the product of step (a) with a lipophilic quenching agent including at least one quenching moiety attached to a lipophilic moiety, under conditions and for a time sufficient to allow the unreacted agent to bond covalently to the quenching moiety; and (c) separating the lipophilic quenching agent and the quenched inactivating agent from the biological composition.
Type:
Grant
Filed:
September 6, 2000
Date of Patent:
September 9, 2003
Assignee:
V. I. Technologies, Inc.
Inventors:
Clark M. Edson, Andrei A. Purmal, Samuel K. Ackerman
Abstract: The present invention provides proteins capable of modulating or mediating the FAS receptor ligand or TNF effect on cells carrying FAS receptor or p55 receptor by binding or interacting with MORT-1 protein, which in turn binds to the intracellular domain of the FAS receptor or to another protein TRADD which binds to the p55 receptor. In addition, peptide inhibitors which interfere with the proteolytic activity of MORT-1-biding proteins having proteolytic activity are provided as well as a method of designing them.
Type:
Grant
Filed:
March 1, 2000
Date of Patent:
July 1, 2003
Assignee:
Yeda Research and Development Co. Ltd.
Inventors:
David Wallach, Mark Boldin, Tanya Goncharov, Yury V. Golstev
Abstract: The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically.
Type:
Grant
Filed:
April 7, 1999
Date of Patent:
July 1, 2003
Assignee:
Scios, Inc.
Inventors:
J. Jeffrey Seilhamer, John Lewicki, Robert M. Scarborough, J. Gordon Porter
Abstract: Nucleic acids are made by converting a primed single-stranded DNA to a double-stranded DNA by a method comprising the step contacting the single-stranded DNA with a DNA polymerase having 5′ exonuclease activity under conditions whereby the DNA polymerase converts the-single stranded DNA to the double-stranded DNA, wherein the single-stranded DNA is primed with oligonucleotide primer comprising a sequence complementary to the 3′ end of the single-stranded DNA, and at least one of the 5′ end of the primer and the single-stranded DNA comprises an RNA polymerase promoter joined to an upstream (5′) flanking moiety which protects the promoter from the 5′ exonuclease activity of the DNA polymerase.
Type:
Grant
Filed:
May 8, 2000
Date of Patent:
June 24, 2003
Assignee:
The Regents of the University of California
Inventors:
Tito Serafini, Percy Luu, John Ngai, David Lin
Abstract: Novel DRT111 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to an isolated, full-length DRT111 protein, the invention further provides isolated DRT111 fusion proteins, antigenic peptides and anti-DRT111 antibodies. The invention also provides DRT111 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a DRT111 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
Abstract: Combinatorial libraries comprise first oligonucleotide analogs and second oligonucleotide analogs which are coupled together to form antisense molecules capable of binding target polynucleotides and activating an RNase, and ribozymes capable of cleaving polynucleotides.
Type:
Grant
Filed:
August 18, 1998
Date of Patent:
February 11, 2003
Assignee:
Oasis Biosciences Incorporated
Inventors:
Timothy A. Riley, Bob D. Brown, Lyle J. Arnold
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of GU Protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding GU Protein. Methods of using these compounds for modulation of GU Protein expression and for treatment of diseases associated with expression of GU Protein are provided.
Type:
Grant
Filed:
April 27, 2001
Date of Patent:
December 10, 2002
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
C. Frank Bennett, Harris Busch, Jacqueline Wyatt
Abstract: The present invention provides synthetic ribozyme oligonucleotides alone and within constructs. The ribozyme gene provides methods for the treatment of prostate hyperplasia and other androgen dependent pathologies. Improved therapies for such diseases are provided without significant hormonal imbalance and without surgical intervention. Also provided are techniques for selecting and synthesizing effective and specifically targeted molecular tools for use in inhibiting androgen receptor gene expression.
Type:
Grant
Filed:
May 8, 1997
Date of Patent:
December 3, 2002
Assignee:
Board of Regents, The University of Texas System
Abstract: To provide a heat shock transcription factor (HSF) 2 binding factor, which can be involved in the transcriptional regulation of HSP70.2 playing an essential role in spermatogenesis; a DNA encoding the binding factor; an expression vector carrying the DNA; a transformant harboring the expression vector; a process for preparing a recombinant protein comprising the step of culturing the transformant; an antibody or a fragment thereof capable of specifically binding to the binding factor; an antisense DNA or antisense RNA complementary to the DNA; and an oligonudeotide probe or primer capable of specifically hybridizing to the DNA.
Type:
Grant
Filed:
August 14, 2000
Date of Patent:
November 26, 2002
Assignee:
HSP Research Institute, Inc.
Inventors:
Tadahiko Yoshima, Hideki Yanagi, Takashi Yura
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Dual specific phosphatase 8. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Dual specific phosphatase 8. Methods of using these compounds for modulation of Dual specific phosphatase 8 expression and for treatment of diseases associated with expression of Dual specific phosphatase 8 are provided.
Abstract: The present invention discloses expression constructs and methods for employing them that result in the modulation of abnormal oncogene and tumor suppressor genes in a novel approach to cancer prevention and therapy. In one embodiment, an expression construct expresses a ribozyme that inactivates mutant p53 and also expresses the functional p53.
Type:
Grant
Filed:
September 1, 1995
Date of Patent:
November 19, 2002
Assignee:
Board of Regents, The University of Texas System
Inventors:
Jack A. Roth, De Wei Cai, Tapas Mukhopadhyay
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Apaf-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Apaf-1. Methods of using these compounds for modulation of Apaf-1 expression and for treatment of diseases associated with expression of Apaf-1 are provided.
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of bifunctional apoptosis regulator. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bifunctional apoptosis regulator. Methods of using these compounds for modulation of bifunctional apoptosis regulator expression and for treatment of diseases associated with expression of bifunctional apoptosis regulator are provided.
Abstract: A pharmaceutical composition is disclosed comprising (A) and oligonucleotide having 5 to 50 nucleotide units, which is specifically hybridizable with DNA or RNA derived from a protein kinase C gene, entrapped in (B) sterically stabilized liposomes.
Type:
Grant
Filed:
March 4, 1999
Date of Patent:
October 15, 2002
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
Paul Leslie Nicklin, Judith Ann Phillips, William Guy Love, Karen Ophelia Hamilton
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Protein Phosphatase 2 catalytic subunit alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein Phosphatase 2 catalytic subunit alpha. Methods of using these compounds for modulation of Protein Phosphatase 2 catalytic subunit alpha expression and for treatment of diseases associated with expression of Protein Phosphatase 2 catalytic subunit alpha are provided.
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phosphorylase kinase alpha 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phosphorylase kinase alpha 2. Methods of using these compounds for modulation of Phosphorylase kinase alpha 2 expression and for treatment of diseases associated with expression of Phosphorylase kinase alpha 2 are provided.
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of serum amyloid A4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding serum amyloid A4. Methods of using these compounds for modulation of serum amyloid A4 expression and for treatment of diseases associated with expression of serum amyloid A4 are provided.
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Casein kinase 2-alpha prime. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Casein kinase 2-alpha prime. Methods of using these compounds for modulation of Casein kinase 2-alpha prime expression and for treatment of diseases associated with expression of Casein kinase 2-alpha prime are provided.
Type:
Grant
Filed:
February 8, 2001
Date of Patent:
September 24, 2002
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
Robert McKay, Susan M. Freier, Jacqueline Wyatt